R RELAY THERAPEUTICS INC
| Market Cap | $1.81B |
| P/E Ratio | — |
| Forward P/E | -6.56 |
| Dividend Yield | — |
| Beta | 1.62 |
| 52W Range | $1.78 - $11.43 |
| # Hedge Funds | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 0 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|
Insider Trading
| Insider Name of the company insider who made the trade 19 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Catinazzo ThomasChief Financial Officer | Sale | 17,717 | $10.06 | $178.23K | 09 Mar 2026 | 09 Mar 2026 |
| Catinazzo ThomasChief Financial Officer | Sale | 1,695 | $8.45 | $14.32K | 28 Jan 2026 | 29 Jan 2026 |
| Rahmer PeterSee remarks | Sale | 1,354 | $8.45 | $11.44K | 28 Jan 2026 | 29 Jan 2026 |
| Bergstrom Donald APresident, R&D | Sale | 2,686 | $8.45 | $22.70K | 28 Jan 2026 | 29 Jan 2026 |
| Catinazzo ThomasChief Financial Officer | Sale | 13,820 | $7.62 | $105.31K | 27 Jan 2026 | 29 Jan 2026 |
| Rahmer PeterSee remarks | Sale | 11,684 | $7.62 | $89.03K | 27 Jan 2026 | 29 Jan 2026 |
| Bergstrom Donald APresident, R&D | Sale | 18,895 | $7.62 | $143.98K | 27 Jan 2026 | 29 Jan 2026 |
| Patel SanjivPresident and CEO | Sale | 43,168 | $7.82 | $337.57K | 06 Jan 2026 | 07 Jan 2026 |
| Sanjiv PatelPresident and CEO | Sale | 43,168 | $7.82 | $337.57K | 06 Jan 2026 | 07 Jan 2026 |
| Patel SanjivPresident and CEO | Sale | 62,073 | $7.00 | $434.51K | 03 Nov 2025 | 04 Nov 2025 |
| Sanjiv PatelPresident and CEO | Sale | 62,073 | $7.00 | $434.51K | 03 Nov 2025 | 04 Nov 2025 |
| Rahmer PeterSee remarks | Sale | 21,394 | $7.50 | $160.46K | 29 Oct 2025 | 30 Oct 2025 |
| Peter RahmerChief Corporate Development Officer; Exhibit 24 - Power of Attorney | Sale | 21,394 | $7.50 | $160.46K | 29 Oct 2025 | 30 Oct 2025 |
| Catinazzo ThomasChief Financial Officer | Sale | 21,664 | $7.29 | $157.93K | 28 Oct 2025 | 30 Oct 2025 |
| Rahmer PeterSee remarks | Sale | 19,135 | $7.29 | $139.49K | 28 Oct 2025 | 30 Oct 2025 |
| Bergstrom Donald APresident, R&D | Sale | 30,897 | $7.29 | $225.24K | 28 Oct 2025 | 30 Oct 2025 |
| Peter RahmerChief Corporate Development Officer; Exhibit 24 - Power of Attorney | Sale | 19,135 | $7.29 | $139.49K | 28 Oct 2025 | 30 Oct 2025 |
| Thomas CatinazzoChief Financial Officer | Sale | 21,664 | $7.29 | $157.93K | 28 Oct 2025 | 30 Oct 2025 |
| Donald A BergstromPresident, R&D | Sale | 30,897 | $7.29 | $225.24K | 28 Oct 2025 | 30 Oct 2025 |
Frequently Asked Questions
What is RLAY stock price today?
RELAY THERAPEUTICS INC (RLAY) is currently trading at $10.15. The stock has a 52-week range of $1.78 to $11.43 and a market capitalization of $1.81B.
Is RLAY a good stock to buy in 2026?
RELAY THERAPEUTICS INC has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +203.7%. 0 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling RLAY stock?
There have been 19 insider transactions for RLAY in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has RLAY stock performed over the past year?
RELAY THERAPEUTICS INC (RLAY) has returned +203.7% over the past 12 months. The stock traded between $1.78 and $11.43 during this period, and is currently at $10.15.
Which hedge funds own RLAY (RELAY THERAPEUTICS INC)?
0 tracked hedge funds currently hold RLAY in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is RLAY's market cap and valuation?
RELAY THERAPEUTICS INC (RLAY) has a market capitalization of $1.81B. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is RLAY's revenue and profitability?
RELAY THERAPEUTICS INC reported revenue of $15.36M with net income of N/A and a profit margin of N/A. The stock has a beta of 1.62.
What sector is RLAY in and who are its biggest institutional holders?
RELAY THERAPEUTICS INC (RLAY) operates in the Healthcare sector. It is held by 0 tracked hedge funds. See the ownership table above for the complete list.